OK I see they have 46 million shares outstanding (shouldn't trust yahoo) so the market cap is in the ~225million US neighborhood. At first I saw they owned 82% of OPLI and saw their market cap and thought it really odd.
how do you think their Psoriasis drug would stack up with Fumarate or if XNPT develops their "better" BG-12?
The first hurdle is beating the current cheap and well known oral drug - methotrexate on safety and efficacy. Then there are the new and advanced oral drugs in development: Pfizer's tofacitinib and CELG’s apremilast. Fumaderm is very effective but has SE like flushing, nausea, vomiting and diarrhea in 30% of patients which typically limit the treatment period to 4-6 weeks plus it is only approved in the EU and mainly in use in Germany.